![Marcus Hanley](https://profiles-cardiff.imgix.net/attachments/1048?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Mr Marcus Hanley
Research Associate
School of Biosciences
Overview
I am biologist with 20 years drug discovery experience across Respiratory and CNS disease areas both within industry and acedmia. Whilst my main remit is to provide in vitro DMPK support for the chemistry programs both here at the MDI and the Sussex Drug Discovery Centre I also provide biochemical/cell based assay development and molecular biology support as required. As of june 2019 I will be embarking on a PhD studying the downstream effects of FMRP1 dysfunction in Fragile-X syndrome.
Publication
2024
- Henderson, S. et al. 2024. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases. European Journal of Medicinal Chemistry 269, article number: 16292. (10.1016/j.ejmech.2024.116292)
2023
- Waller-Evans, H., Zhu, J., Honeybun, L., Gardiner, S., Hanley, M., Best, H. and Lloyd-Evans, E. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 133-134., (10.1016/j.ymgme.2022.107353)
2021
- Henderson, S. H. et al. 2021. Discovery and characterization of selective and ligand-efficient DYRK inhibitors. Journal of Medicinal Chemistry 64(15), pp. 11709–11728. (10.1021/acs.jmedchem.1c01115)
Articles
- Henderson, S. et al. 2024. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases. European Journal of Medicinal Chemistry 269, article number: 16292. (10.1016/j.ejmech.2024.116292)
- Henderson, S. H. et al. 2021. Discovery and characterization of selective and ligand-efficient DYRK inhibitors. Journal of Medicinal Chemistry 64(15), pp. 11709–11728. (10.1021/acs.jmedchem.1c01115)
Conferences
- Waller-Evans, H., Zhu, J., Honeybun, L., Gardiner, S., Hanley, M., Best, H. and Lloyd-Evans, E. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 133-134., (10.1016/j.ymgme.2022.107353)
Research
After 20 years working in drug Discovery both within industry and academia serving numerous and varied projects I have acquired a broad skill base with which to support MDI activities in a addition to provision of DMPK anayses.
Cloning / Protein expression - DNA/RNA purification, Sanger sequencing, Cloning (Bacterial / Mammalian / Insect expression vectors), Protein expression and purification (Various chromatographic / affinity based methods), Mutant generation, Chromosomal mapping, Real time qPCR (including allelic discrimination).
Biochemical/ cell based assay development - TR-FRET, Fluorescence, Luminescence, FLIPR, ELISA, Transient expression, siRNA inhibition, Transient expression.
Other - Cell culture (primary cells/cell lines), differentiation of primary cell lines to terminal phenotype (HBECs at air/liquid interface).
Biography
Howard TD, Whittaker PA, Zaiman AL, Koppelman GH, Xu J, Hanley MT, Meyers DA, Postma DS, Bleeker ER. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. About J Respir Cell Mol Biol. 2001 Sep;25(3):377-84.
Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. 2003 May;139(1):163-71.
Academic positions
2013-2018; Research Fellow, Sussex Drug Discovery Centre, Sussex University
Contact Details
+44 29225 11075
Main Building, Park Place, Cardiff, CF10 3AT
Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX